Renoprotective effect of tolvaptan in patients with new ‐onset acute heart failure

ConclusionsA lower incidence of WRF was observed in patients with new ‐onset AHF who were treated with the tolvaptan add‐on therapy, specifically those with left ventricular systolic dysfunction and renal impairment on admission.

Source: ESC Heart Failure - May 6, 2020 Category: Cardiology Authors: Hiromi Kin, Koichiro Matsumura, Yoshihiro Yamamoto, Kenichi Fujii, Munemitsu Otagaki, Hiroki Takahashi, Haengnam Park, Kei Yoshioka, Mitsuru Yokoi, Tetsuro Sugiura, Ichiro Shiojima Tags: Original Research Article Source Type: research